Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Enzalutamide
Related studies linked through entity extraction aliases.
Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)
- Status
- RECRUITING
- Phase
- PHASE2
Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC
- Status
- RECRUITING
- Phase
- PHASE2
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings
- Status
- COMPLETED
- Phase
- N/A
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely
- Status
- COMPLETED
- Phase
- N/A
Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE2
EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer
- Status
- TERMINATED
- Phase
- PHASE1
FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension
- Status
- COMPLETED
- Phase
- PHASE3
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2